Glycoengineering of plant-produced Pembrolizumab enhances FcRn binding and extends serum half-life in mice
Biotechnology Reports · 2025-12 · 48 · e00927
DOI: 10.1016/j.btre.2025.e00927 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Reports, 2025-12. Verfasst von Christine Joy I Bulaon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Baiya Phytopharm Co., Ltd, Bangkok, 10330, Thailand. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universität für Bodenkultur Wien, Chulalongkorn University.
Abstract (Originalsprache)
Plant systems offer scalable and cost-effective platforms for antibody production, but plant-specific glycans may affect pharmacokinetics and immunogenicity. To evaluate the impact of Fc glycosylation, four Pembrolizumab glycovariants were generated in Nicotiana benthamiana: wild-type glycosylation (Pembro-WT), high-mannose with SEKDEL (Pembro-KD), aglycosylated N297A mutant (Pembro-NG), and a core fucose/xylose-deficient variant (Pembro-XF). Glycoproteins were transiently expressed either in wild-type or ΔXF plants, purified, and characterized for glycan composition, in vitro binding, and in vivo pharmacokinetics. LC-MS confirmed distinct glycoform patterns, while PD-1 binding was retained across all variants. Pembro-XF showed the highest FcRn binding affinity and longest serum half-life (45.83 h) in mice, compared to Pembro-WT (26.7 h), Pembro-KD (32.95 h), Pembro-NG (34.27 h), and Keytruda® (33.26 h). As an initial efficacy evaluation, Pembro-WT demonstrated strong antitumor activity in a murine colon cancer model. These findings support plant glycoengineering as a strategy to enhance antibody pharmacokinetics and advance next generation antibody therapeutics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Baiya Phytopharm Co., Ltd, Bangkok, 10330, Thailand.
- Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
- GemPharmatech Co., Ltd, Nanjing, China.
- Center of Excellence for Antibody Research, Faculty of Tropical Medicine, Mahidol University, Thailand.
- Department of Social and Environmental Medicine, Faculty of Tropical Medicine, Mahidol University, Thailand.
- Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Förderung
- Universität für Bodenkultur Wien
- Chulalongkorn University
Zitieren
APA
Bulaon, C. J. I., Jaratsittisin, J., Rattanapisit, K., Suwanchaikasem, P., Guo, S., Boonha, K., Pitaksajjakul, P., Simsom, N., Limprasutr, V., & Phoolcharoen, W. (2025). Glycoengineering of plant-produced Pembrolizumab enhances FcRn binding and extends serum half-life in mice. Biotechnology Reports, 48, e00927. https://doi.org/10.1016/j.btre.2025.e00927
Vancouver
Bulaon CJI, Jaratsittisin J, Rattanapisit K, Suwanchaikasem P, Guo S, Boonha K, et al. Glycoengineering of plant-produced Pembrolizumab enhances FcRn binding and extends serum half-life in mice. Biotechnology Reports. 2025;48:e00927. doi:10.1016/j.btre.2025.e00927
BibTeX
@article{Bulaon2025,
author = {Bulaon, Christine Joy I and Jaratsittisin, Janejira and Rattanapisit, Kaewta and Suwanchaikasem, Pipob and Guo, Shiying and Boonha, Khwanchit and Pitaksajjakul, Pannamthip and Simsom, Nipaporn and Limprasutr, Vudhiporn and Phoolcharoen, Waranyoo},
title = {Glycoengineering of plant-produced Pembrolizumab enhances FcRn binding and extends serum half-life in mice},
journal = {Biotechnology Reports},
year = {2025},
volume = {48},
pages = {e00927},
doi = {10.1016/j.btre.2025.e00927}
}
EUVIMED